AntibioticDB

Highest development stage: Approved in 1953

Development status: Experimental

Mechanism of Action/Target pathogen: Active against Mycobacterium tuberculosis. Mycobacterium ranae, Mycobacterium phlei, and Mycobacterium smegmatis; protein synthesis inhibitor (blocks elongation factor G-mediated translocation of mRNA)

Additional information: Natural product from Streptomyces puniceus; administered via injection; used as second line anti-tubercular drug

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13252

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765823/

Citation (1): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743798/

Citation (2): https://www.pnas.org/doi/full/10.1073/pnas.2002888117

Citation (3): https://www.atsjournals.org/doi/epdf/10.1164/art.1951.63.1.1?role=tab

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/135398671

Viomycin, celiomycin, florimycin, tuberactinomycin B, viocin

Tuberactinomycin

Research Laboratories of Parke, Davis & Company, Detroit Michigan USA; Research Laboratories, Chas. Pfizer & Co., Inc., Brooklyn, New York, USA

1951